June 12, 2019 / 5:08 AM / 6 months ago

BRIEF-FDA Grants Priority Review To Roche’S Rituximab In Children With Blood Vessel Disorders

June 12 (Reuters) - Roche Holding AG:

* FDA GRANTS PRIORITY REVIEW TO GENENTECH’S RITUXAN (RITUXIMAB) IN CHILDREN WITH TWO RARE BLOOD VESSEL DISORDERS

* PEPRS STUDY IS FIRST GLOBAL TRIAL OF RITUXAN IN PEDIATRIC PATIENTS WITH GPA OR MPA

* RITUXAN IN COMBINATION WITH GLUCOCORTICOIDS IS ONLY FDA-APPROVED THERAPY FOR ADULTS WITH THESE TWO RARE FORMS OF VASCULITIS

* IF APPROVED, THIS WOULD BE FIRST PEDIATRIC INDICATION FOR RITUXAN Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below